Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection
A Gharbharan, CCE Jordans… - Nature …, 2021 - nature.com
In a randomized clinical trial of 86 hospitalized COVID-19 patients comparing standard care
to treatment with 300mL convalescent plasma containing high titers of neutralizing SARS-…
to treatment with 300mL convalescent plasma containing high titers of neutralizing SARS-…
Convalescent plasma for COVID-19. A randomized clinical trial
A Gharbharan, CCE Jordans, C Geurtsvankessel… - MEDRxiv, 2020 - medrxiv.org
Structured abstract for full paper Background After recovery from COVID-19, most patients
have anti-SARS-CoV-2 neutralizing antibodies. Their convalescent plasma could be an …
have anti-SARS-CoV-2 neutralizing antibodies. Their convalescent plasma could be an …
[HTML][HTML] Outpatient convalescent plasma therapy for high-risk patients with early COVID-19: a randomized placebo-controlled trial
A Gharbharan, C Jordans, L Zwaginga… - Clinical Microbiology …, 2023 - Elsevier
Objectives The potential benefit of convalescent plasma (CP) therapy for coronavirus disease
2019 (COVID-19) is highest when administered early after symptom onset. Our objective …
2019 (COVID-19) is highest when administered early after symptom onset. Our objective …
Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients
P Millat-Martinez, A Gharbharan, A Alemany… - Nature …, 2022 - nature.com
Data on convalescent plasma (CP) treatment in COVID-19 outpatients are scarce. We aimed
to assess whether CP administered during the first week of symptoms reduced the disease …
to assess whether CP administered during the first week of symptoms reduced the disease …
A comparative study of software programmes for cross‐sectional skeletal muscle and adipose tissue measurements on abdominal computed tomography scans of …
JLA van Vugt, S Levolger, A Gharbharan… - Journal of cachexia …, 2017 - Wiley Online Library
Background The association between body composition (eg sarcopenia or visceral obesity)
and treatment outcomes, such as survival, using single‐slice computed tomography (CT)‐…
and treatment outcomes, such as survival, using single‐slice computed tomography (CT)‐…
Interferon-α2 auto-antibodies in convalescent plasma therapy for COVID-19
MP Raadsen, A Gharbharan, CCE Jordans… - Journal of clinical …, 2022 - Springer
Purpose To study the effect of interferon-α2 auto-antibodies (IFN-α2 Abs) on clinical and
virological outcomes in critically ill COVID-19 patients and the risk of IFN-α2 Abs transfer during …
virological outcomes in critically ill COVID-19 patients and the risk of IFN-α2 Abs transfer during …
Coronavirus disease 2019 convalescent plasma outpatient therapy to prevent outpatient hospitalization: a meta-analysis of individual participant data from 5 …
…, DF Hanley, BJA Rijnders, A Gharbharan… - Clinical Infectious …, 2023 - academic.oup.com
Background Outpatient monoclonal antibodies are no longer effective and antiviral treatments
for coronavirus disease 2019 (COVID-19) disease remain largely unavailable in many …
for coronavirus disease 2019 (COVID-19) disease remain largely unavailable in many …
Association of convalescent plasma treatment with clinical status in patients hospitalized with COVID-19: a meta-analysis
…, KJ Bar, T Devos, RF Duarte, A Gharbharan… - JAMA Network …, 2022 - jamanetwork.com
Importance COVID-19 convalescent plasma (CCP) is a potentially beneficial treatment for
COVID-19 that requires rigorous testing. Objective To compile individual patient data from …
COVID-19 that requires rigorous testing. Objective To compile individual patient data from …
Sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the severe acute respiratory syndrome coronavirus 2 …
…, B Oude Munnink, A Gharbharan… - Clinical Infectious …, 2023 - academic.oup.com
Viral evolution was evaluated in 47 immunocompromised patients treated with sotrovimab.
Sequencing of SARS-CoV-2 following therapy was successful in 16. Mutations associated …
Sequencing of SARS-CoV-2 following therapy was successful in 16. Mutations associated …
High-titer convalescent plasma plus nirmatrelvir/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patients
S Huygens, A Gharbharan, Y Serroukh… - Journal of …, 2023 - academic.oup.com
Objectives Immunocompromised patients have an increased risk of severe or prolonged
COVID-19. Currently available drugs are registered to treat COVID-19 during the first 5 to 7 …
COVID-19. Currently available drugs are registered to treat COVID-19 during the first 5 to 7 …
